Journal of Laboratory Medicine and Quality Assurance

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2288-7261   pISSN 2384-2458

Table. 16.

Table. 16.

2017 external quality assessment result of rapid antituberculous drug resistance test (isoniazid)

MTB DNA, drug (isoniazid) resistance mutation1st trial2nd trial3rd trial



GT1703GT1704GT1708GT1709GT1713GT1714






R (%)S (%)R (%)S (%)R (%)S (%)R (%)S (%)R (%)S (%)R (%)S (%)
Hain Lifescience13 (100)13 (100)13 (100)13 (100)12 (100)12 (100)
 GenoType MTBDRplus13 (100)13 (100)13 (100)13 (100)12 (100)12 (100)
LG Chem6 (100)6 (100)6 (100)6 (100)7 (100)7 (100)
 AdvanSure MDR-TB GenoBlot Assay6 (100)6 (100)6 (100)6 (100)7 (100)7 (100)
Others4 (100)4 (100)4 (100)4 (100)4 (100)4 (100)
Seegene3 (100)3 (100)3 (100)3 (100)4 (100)4 (100)
 Seegene anyplex MDR-TB detection3 (100)3 (100)3 (100)3 (100)4 (100)4 (100)
YD Diagnostics1 (100)1 (100)1 (100)1 (100)
 MolecuTech REBA MTB-MDR1 (100)1 (100)1 (100)1 (100)
All26 (100)26 (100)27 (100)27 (100)28 (100)28 (100)

The instrument used was from the following company: Hain Lifescience (Nehren, Germany); LG Chemical (Seoul, Korea); Seegene (Seoul, Korea); and YD Diagnostics (Yongin, Korea).

Abbreviations: MTB, Mycobacterium tuberculosis; R, resistant; S, susceptible.

J Lab Med Qual Assur 2019;41:82-104 https://doi.org/10.15263/jlmqa.2019.41.2.82
© 2019 J Lab Med Qual Assur